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osting by EAbstract The current study evaluated the antihyperglycemic and hypolipidaemic effects of meth-
anolic extract of Viscum schimperi Engl. whole parts in streptozotocin (STZ)-induced diabetic rats.
The antihyperglycemic activity was evaluated by measuring the fasting blood glucose level (BGL)
and by applying the oral glucose tolerance test (OGTT) in diabetic rats. In addition, the effect of
the extract on blood plasma insulin was measured as well as its effect on tissue glycogen contents
in muscle and liver. The hypolipidaemic effect was evaluated by assaying triglyceride (TG), total
cholesterol (TC), high density lipoprotein cholesterol (HDL-C) and low density lipoprotein-choles-
terol (LDL-C). Diabetic male Wistar rats of a same age group were treated orally once a day for
4 weeks with a dose of 500 mg/kg bw of methanolic extract. Fasting BGL was measured on the
7th, 14th, 21st and 28th days, while plasma insulin levels were measured at the end of the 28th
day. Maximum reduction in BGL of 37% was observed at the 4th week. Furthermore, there was737784; fax: +202 25320005.
(E.A. Abdel-Sattar).
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172 E.A. Abdel-Sattar et al.a signiﬁcant increase in plasma insulin, by 321.6%. The hypolipidaemic effect was demonstrated by
signiﬁcant reductions in plasma TC (32.6%), in TG (32.2%) and in LDL-C (27.2%); and an
increase in HDL-C of 171.5%. The present data suggest that V. schimperi has both antihyperglyce-
mic and hypolipidaemic effects with high insulin-secreting activity.
ª 2011 Cairo University. Production and hosting by Elsevier B.V. All rights reserved.Introduction
In recent years, developed nations have witnessed an explosive
increase in the prevalence of diabetes mellitus (DM), predom-
inantly related to lifestyle changes and the resulting surge in
obesity [1]. Diabetes mellitus is a metabolic disorder, charac-
terized by hyperglycemia together with impaired metabolism
of glucose and other energy-yielding fuels such as lipids and
proteins [2]. This metabolic disorder is due to deﬁciency in
insulin secretion or resistance to insulin action or both [3].
Dyslipidemia or hyperlipidemia is also involved in the develop-
ment of cardiovascular complications in diabetes, which are
the major causes of morbidity and mortality [4]. Longstanding
diabetes, poor glycemic control, hypertension and dyslipide-
mia can lead to the development of diabetic vascular complica-
tions [5].
Renewed attention to alternative medicines and natural
therapies has channeled research interest towards traditional
herbal medicine. Because of their perceived effectiveness, min-
imal side effects in clinical experience and relatively low costs,
herbal drugs are prescribed widely even when their biologically
active compounds are unknown [6]. Extracts of the European
mistletoe (Viscum album L.) have been used for several decades
against a variety of diseases. A tea prepared from the leaves of
mistletoe is used traditionally to treat diabetes in the West In-
dies [7]. V. album has been shown also to relieve the diabetic
symptoms of severely hyperglycaemic streptozotocin-diabetic
mice [8]. Mistletoes have shown the ability to lower blood pres-
sure, slow the heart beat, stimulate the immune system, relax
spasms and exert sedative, diuretic and anti-cancer effects
[9]. They have also shown insulin-secreting activity [10]. From
Viscum extracts, different components with cytotoxic, immu-
noactive, and tumour-inhibiting properties have been identi-
ﬁed, including the three types of ribosome-inactivating
proteins, mistletoe lectins I–III, class 3 thionins (viscotoxins
A1, A2, A3, B, 1-Ps), polysaccharides, oligosaccharides and
alkaloids [11].
In a continuation of our interest in the chemical composi-
tion and biological activity of Saudi mistletoe, Viscum
schimperi Engl., we investigated it for its antidiabetic and hyp-
olipidaemic activities in streptozotocin (STZ)-induced diabetic
rats.Material and methods
Plant material and extraction
The aerial parts of V. schimperi Engl. were collected from the
Al-Sheffa area, Al-Taif governorate, Saudi Arabia, in March
2008 and were dried in shade. The plant was identiﬁed by
Dr. Farag A. Al-Ghamdi, Department of Biology, College of
Science, King Abdulaziz University, Jeddah, Saudi Arabia.
A specimen (V. schimperi Engl. #VS1167) was deposited inthe herbarium of the College of Pharmacy, King Abdulaziz
University, Jeddah, Saudi Arabia. The powdered plant mate-
rial (500 g) was extracted with methanol using Ultraturrax
T25 homogeniser (Janke & Kunkel, IKA Labortechnik, Sta-
uten, Germany) (3 · 2000 ml). The vehicle was distilled off un-
der reduced pressure and the dried methanolic extract was kept
at 4 C.
Chemicals
Streptozotocin (STZ) and a-D-glucose were purchased from
Sigma–Aldrich (St. Louis, MO, USA). Carboxymethylcellu-
lose sodium (CMC-Na) was purchased from Acros Organics
(NJ, USA), while heparin sodium was purchased from Merck
(Dramstadt, Germany). Insulin kit (Coat-A-Count Insulin)
was purchased from Siemens Medical Solutions Diagnostics
(Los Angeles, USA). All other biodiagnostic kits were pur-
chased from Diagnostic and Research Reagents (Giza, Egypt).
Animals
Male Wistar rats, weighing 150–200 g, were used in this study
in accordance with the guidelines of the Biochemical and Re-
search Ethical Committee at King Abdulaziz University, Jed-
dah, Saudi Arabia, (which accord with the NIH guidelines).
Animals were purchased from the animal house of King Fahed
Medical Research Center, King Abdulaziz University. They
were housed for 2 days under standard conditions (well venti-
lated, temperature 22 ± 2 C, relative humidity 50–60% and
12 h day and night cycle). Food consisted of normal rat chow
and water was provided ad libitum. Care was taken to avoid
stressful conditions. All experimental procedures were per-
formed from 8 to 10 a.m.
All the experimental work with the animals was carried out
after obtaining approval from the Institutional Animal Ethical
Committee.
Acute toxicity study
Twenty-four adult male Wistar rats were used and divided into
four groups receiving V. shimperi extract at increasing doses of
100, 250, 500 and 1000 mg/kg daily for a period of 3 weeks (six
rats were used for each dose). The animals were observed dur-
ing the ﬁrst hour continuously and then every hour for 6 h, then
after 12 and 24 h, and ﬁnally after every 24 h up to 3 weeks, for
any physical signs of toxicity such as writhing, gasping, palpita-
tion and decreased respiratory rate or mortality.
Induction of diabetes and experimental design
Diabetes was induced by an ip injection of a fresh solution of a
single dose of STZ (in 0.1 M sodium citrate buffer, pH 4.5) in a
dose of 55 mg/kg body weight, to overnight fasting rats [12].
Ten days after STZ administration, rats with fasting BGL
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divided into three groups (groups II–IV).
Thirty-two rats were randomly divided into four groups,
eight animals in each group:
 Group I (normal control) received an equivalent volume of
the 0.1 M sodium citrate buffer.
 Group II (diabetic group) received a single daily dose of 1%
CMC-Na starting at the 11th day, and this group served as
the ve control group.
 Group III (glibenclamide group) diabetic rats received a sin-
gle daily dose of glibenclamide in a dose of 5 mg/kg starting
at the 11th day and served as the +ve control group.
 Group IV (V. schimperi group) diabetic rats received the
plant extract of V. schimperi in a dose of 500 mg/kg body -
weight each as a single daily dose starting at the 11th day.
The dosage of the extract was determined at 500 mg/kg/
day [13] from a preliminary short-term pilot study in our
laboratory using a range of variable doses.
Vehicle, glibenclamide and plant extract were given orally
by gavage as single daily treatments for 4 weeks. Blood sam-
ples were collected from the tail vein and fasting BGL of the
overnight fasted animals was measured before and at days 7,
14, 21 and 28 from the treatment.
At the end of the experiment, blood samples were with-
drawn from the orbital sinus and animals were sacriﬁced by
cervical dislocation under light ether anesthesia for separation
of the liver. Livers were dissected out and kept in liquid nitro-
gen. Liver and muscle tissues were excised, blotted, weighed
and stored at 80 C for assay of glycogen content.
Estimation of plasma insulin level
At the end of the 28th day, 3 h after the last dose of the vehicle,
glibenclamide or the extract, blood samples were withdrawn
from the orbital sinus of rats under light ether anesthesia into
heparinized tubes. Samples were centrifuged at 3500g for
15 min for separation of plasma. Plasma samples were sepa-
rated and kept at 20 C for analysis when required. Insulin
concentrations were determined by radioimmunoassay proce-
dure using insulin kits.
Estimation of plasma glucose and tissue glycogen
Fasting plasma glucose was estimated using glucose oxidase
peroxidase method [14]. Tissue glycogen was estimated by
the method of Morales et al. (1973) [15].
Estimation of plasma lipid proﬁle
Blood lipids were determined using spectrophotometric assay
techniques. Plasma of normal (group I), diabetic control
(group II) and diabetic-treated (groups III and IV) rats were
used for the determination of plasma TC, TG, LDL-C and
HDL-C.
Oral glucose tolerance test (OGTT)
Twenty-four male Wistar rats were divided into four groups
(six rats in each group) as shown in the experimental design.
At the end of the 28th day, 3 h after the last dose of the vehicle,glibenclamide or the extract, blood samples were withdrawn
from the tail vein of overnight fasting rats and BGL was deter-
mined, indicating zero time of the test. Glucose solution (50%)
in a dose of 2.5 g/kg was given orally [16]. Blood samples were
taken at 15, 30, 60, 90 and 120 min after glucose loading and
BGL were determined at these time intervals using One Touch
Ultra. Curves of BGL (mg/dl) versus the time intervals (min)
were constructed and the area under the curve (AUC) was cal-
culated by the trapezoidal method. The AUCs of the curves of
each group were compared and tested for signiﬁcance against
the control–diabetic group, to represent the glucose tissue
utilization.
Statistical analysis
Data are expressed as mean ± standard error (SE) of mean.
Unless otherwise indicated, statistical analyses were performed
using one-way analysis of variance (ANOVA). If the overall
F-value was found statistically signiﬁcant (P< 0.05), further
comparisons among groups were made according to post hoc
Tukey’s test. All statistical analyses were performed using
SPSS GraphPad InStat 3 (GraphPad Software Inc., La Jolla,
CA, USA) software.Results
Toxicity study
No deaths were reported in the rats treated with different doses
of V. schimperi and rats did not show any apparent physical
signs of drug-induced toxicity during the whole experimental
period.
Effect of extract on plasma glucose level
STZ-diabetic rats showed signiﬁcant increases in the levels of
plasma glucose when compared to normal rats. Glibenclamide
treatment of diabetic rats showed signiﬁcant reduction in plas-
ma glucose level at the 21st day of treatment compared to be-
fore treatment. On the other hand, po administration of V.
schimperi showed highly signiﬁcant reduction in plasma glu-
cose levels starting at the 14th day of treatment compared to
before treatment (Table 1).
Effect of extract on plasma insulin level
The induction of diabetes signiﬁcantly reduced the plasma
insulin level, by 56.9% (Table 2). After 4 weeks of po admin-
istration of glibenclamide, a signiﬁcant increase in plasma
insulin level, by 272.7% of the diabetic control, was produced.
However, treatment of diabetic rats with V. schimperi extract
signiﬁcantly increased the insulin blood level compared to
the diabetic rats, by 321.6% (Table 2).
Effect of extract on muscle and liver glycogen
Table 2 shows the levels of muscle and liver glycogen in normal
diabetic and treated rats. There was a decrease in the muscle
glycogen (79.2%) and liver glycogen (57.3%) content of dia-
betic rats when compared to normal rats. Glibenclamide treat-
ment signiﬁcantly increased both muscle and liver glycogen, by
Table 2 Effects of oral administration of V. schimperi extract (500 mg/kg/day for 4 weeks) on plasma insulin level, muscle glycogen
and liver glycogen in diabetic rats.
Groups Insulin (lIU/ml) Muscle glycogen (mg/g tissue) Liver glycogen (mg/g tissue)
Normal control 7.48 ± 1.32 10.12 ± 0.9 56.43 ± 5.4
Diabetic group 3.22 ± 0.387a 2.10 ± 0.2a 24.12 ± 2.3a
Glibenclamide group 12.47 ± 2.39b 7.41 ± 0.6b 49.13 ± 4.2b
V. schimperi group 13.61 ± 1.72b 8.83 ± 0.8b 50.13 ± 5.2b
The values are expressed as the mean ± SE of the mean of eight rats in each group.
a Signiﬁcantly different from the values of the normal rats at P< 0.05.
b Signiﬁcantly different from the control values of diabetic rats at P< 0.05.
Table 1 Effect of treatment with V. schimpe extract (500 mg/kg/day for 4 weeks) on the blood glucose levels of diabetic rats.
Groups Blood glucose level (mg/dl)
Before treatment After treatment
7th day 14th day 21st day 28th day
Normal control 103 ± 3.8 102 ± 2.9 102 ± 3.6 98 ± 5.7 111 ± 7.5
Diabetic group 394 ± 27.1 406 ± 22.7 433 ± 17.0 470 ± 31.8 494.± 31.2
Glibenclamide group 416 ± 18.7 456 ± 19.6 443 ± 22.7 376 ± 21.7a 335 ± 25.6a
V. schimperi group 425 ± 29.4 485 ± 3.0 395 ± 19.0a 345 ± 30.4a 327 ± 23.7a
The values are expressed as the mean ± SE of the mean of eight rats in each group.
a Statistically signiﬁcant from corresponding before treatment value at P< 0.05.
174 E.A. Abdel-Sattar et al.71.7% and 50.9%, respectively. When V. schimperi was admin-
istered to diabetic rats for 28 days, the muscle and liver glyco-
gen contents increased signiﬁcantly (by 76.2% and 51.9%,
respectively).
Effect of extract on plasma lipid proﬁle
Diabetic rats showed signiﬁcant increase in the blood levels of
TC, TG and LDL-C (Table 3). The recorded increases were
90.9%, 30.3% and 114.3%, respectively, of the values of the
normal rats. On the other hand, HDL-C was signiﬁcantly re-
duced, by 32.4% of the value of the normal rats. Oral admin-
istration of glibenclamide signiﬁcantly decreased the blood
levels of TC and LDL-C, by 25.7% and 33.5% of the diabetic
rats, respectively. However, the level of HDL-C was signiﬁ-
cantly increased, by 103.2%. Glibenclamide did not signiﬁ-
cantly change the blood level of TG. Treatment with V.
schimperi extract signiﬁcantly decreased the blood levels of
TC, TG and LDL-C, by 32.6%, 32.2% and 27.2%, respec-
tively, of diabetic rats; however, the blood level of HDL-C
was signiﬁcantly increased, by 171.5%.
Effect of extract on OGTT
The blood levels of glucose in control, diabetic group, diabetic
treated with glibenclamide or plant extract groups, demon-
strated a signiﬁcant change in BGL after po loading with
50% glucose solution (Fig. 1). The rats of the diabetic group
had a signiﬁcant elevation in BGL throughout the total mea-
surement period (120 min) with respect to normal control
(Fig. 1); also it did not come back to the initial value (0 min
level) even at the end of the period tested (120 min).
Treatment of diabetic rats with glibenclamide induced a sig-
niﬁcant reduction (15%) in the AUC relative to the diabeticcontrol group (Fig. 1). However, treatment of the diabetic rats
with V. schimperi extract, produced a signiﬁcant reduction of
the AUC, by 22% (Fig. 1).
Discussion
Conventional therapies for diabetes have many side effects and
high rate of secondary failure. On the other hand herbal ex-
tracts are expected to have similar efﬁcacy with fewer side ef-
fects than conventional drugs [17]. Nowadays, more than
1200 plant species are used to treat symptoms of diabetes mel-
litus. The hypoglycemic property of almost 50% of these tra-
ditionally consumed medicines has been experimentally
tested [18]. V. schimperi belongs to the Viscaceae family and
members of genus Viscum are traditional hypoglycemic herbs
[19]. The present investigation reports the antihyperglycemic
effect of the methanolic extract of V. schimperi on STZ-in-
duced diabetic rats.
STZ injection resulted in diabetes mellitus close to that of
humans, which is probably due to the destruction of b-cells
of islets of Langerhans as proposed by many authors [20–
22]. This effect is being depicted in our study by elevation of
BGL and decreased insulin levels in STZ-induced diabetic rats.
The increased levels of plasma glucose in diabetic rats were
lowered by the administration of V. schimperi. The reduced
glucose levels suggested that V. schimperi might exert an insu-
lin-like effect on peripheral tissues. Our study indicated that
the hypoglycemic effect of V. schimperi is caused by stimula-
tion and potentiation of insulin release from the remnant exist-
ing beta cells of islets of Langerhans. It caused a large increase
of plasma insulin in STZ-treated rats. This effect of V. schim-
peri seems to be similar to that of glibenclamide which induces
insulin exocytosis from beta cells as proposed by Tian et al.











































































































































































































































































































































































































































































































































































Antidiabetic and hypolipidaemic effects of Saudi mistletoe 175presence of insulin-releasing natural products, including lec-
tins, in V. album, which may contribute to the reported antidi-
abetic property of the plant. The ability of lectins isolated from
mushrooms (Agaricus campestris, Agaricus bisporus) to en-
hance insulin release by isolated rat islets of Langerhans has
been documented [24–26]. Moreover, the antidiabetic proper-
ties of the African mistletoe (Loranthus bengwengis) were
investigated in streptozotocin-diabetic rats and found to be
highly dependent on the host plant species [27]. However, Onal
et al. (2005) [28] demonstrated that V. album has an antidia-
betic activity. This effect may be due to the inhibition of a-glu-
cosidase activity and glucose absorption as V. album contains
lectins, misteloe lectin I, II, III, viscotoxins and cyclitols.
Glycogen synthesis in the rat liver and skeletal muscles was
impaired during diabetes [29]; hence the glycogen content of
skeletal muscle and liver were markedly decreased in diabetes
[30]. Results of the present study showed an increase in skeletal
muscle and liver glycogen content in STZ-diabetic rats after po
administration of V. schimperi. This prevention of glycogen
depletion in both liver and muscles is possibly due to stimula-
tion of insulin release from beta cells [31]. The effect of V.
schimperi extract on glucose tolerance and tissue utilization
of glucose was studied in diabetic rats using the OGTT. OGTT
was reported to measure the rate of tissue uptake and utiliza-
tion of glucose. Diabetic control rats showed a signiﬁcant in-
crease in the AUC of the glucose concentration after po
glucose loading. This effect may be due to the reduction of glu-
cose tissue utilization and increased hepatic glucose produc-
tion as a result of decreased insulin secretion. The partial or
complete destruction of pancreatic b-cells in STZ-diabetic rats
is the main effect [32]. V. schimperi extract produced signiﬁcant
reduction of the AUC of the diabetic control rats. These re-
sults revealed that the V. schimperi extract induced an increase
in glucose utilization and glucose tolerance by the body tissues
of diabetic rats.
It is well known that in uncontrolled type 2 diabetes melli-
tus, TC, LDL-C, VLDL-C and TG increase, while the HDL
levels decline contributing to secondary complications
[33,34]. The abnormally high concentrations of serum lipids
in the diabetic subjects are due mainly to the increase in the
mobilization of free fatty acids from the peripheral fat depots,
since insulin inhibits the hormone sensitive lipase. Insulin deﬁ-
ciency or insulin resistance may be responsible for dyslipide-
mia, because insulin has an inhibitory action on HMG-CoA




























Fig. 1 Effect of V. schimperi extract (500 mg/kg) on the fasting
blood glucose level of diabetic rats during OGTT. The values are
expressed as the mean ± SE of the mean of six rats in each group.
176 E.A. Abdel-Sattar et al.metabolism of cholesterol rich LDL particles. Acute insulin
deﬁciency initially causes an increase in free fatty acid mobili-
zation from adipose tissue. This results in an increased produc-
tion of LDL-C particle [35]. The administration of V.
schimperi increased the level of serum HDL-C and decreased
the levels of TC, TG and LDL-C, which could be secondary
to a partially restored beta-cell function with increased insulin
levels.Conclusion
This study indicates that V. schimperi has both hypoglycemic
effect and antidyslipidemic activity. The possible mechanism
by which V. schimperi brings about its antidiabetic action
may be through stimulation of insulin release from the rem-
nant pancreatic b-cells. Considering the V. schimperi effect
on lipid proﬁle, it may be a potential hypolipidaemic agent,
which will be a great advantage in treating diabetic conditions
associated with atherosclerosis or hyperlipidemia.
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